1. Gasiorowski JZ, Russell P. Biological properties of trabecular meshwork cells.
Exp Eye Res 2009;88:671-675.
2. Bradley JM, Kelley MJ, Zhu X, et al. Effects of mechanical stretching on trabecular matrix metalloproteinases.
Invest Ophthalmol Vis Sci 2001;42:1505-1513.
3. Acott TS, Kelley MJ. Extracellular matrix in the trabecular meshwork.
Exp Eye Res 2008;86:543-561.
4. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork.
Invest Ophthalmol Vis Sci 1991;32:172-180.
5. Borras T. Gene expression in the trabecular meshwork and the influence of intraocular pressure.
Prog Retin Eye Res 2003;22:435-463.
6. Fuchshofer R, Welge-Lussen U, Lutjen-Drecoll E. The effect of TGF-beta2 on human trabecular meshwork extracellular proteolytic system.
Exp Eye Res 2003;77:757-765.
7. Lo WR, Rowlette LL, Caballero M, et al. Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma.
Invest Ophthalmol Vis Sci 2003;44:473-485.
8. Vittal V, Rose A, Gregory KE, et al. Changes in gene expression by trabecular meshwork cells in response to mechanical stretching.
Invest Ophthalmol Vis Sci 2005;46:2857-2868.
9. Oh DJ, Martin JL, Williams AJ, et al. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells.
Invest Ophthalmol Vis Sci 2006;47:3887-3895.
10. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture.
Invest Ophthalmol Vis Sci 1998;39:2649-2658.
11. Grierson I, Hogg P. The proliferative and migratory activities of trabecular meshwork cells.
Prog Retin Eye Res 1995;15:33-67.
12. Alvarado J, Murphy C, Polansky J, Juster R. Age-related changes in trabecular meshwork cellularity.
Invest Ophthalmol Vis Sci 1981;21:714-727.
13. Grierson I, Howes RC. Age-related depletion of the cell population in the human trabecular meshwork.
Eye (Lond) 1987;1(Pt 2):204-210.
14. Grierson I, Wang Q, McMenamin PG, Lee WR. The effects of age and antiglaucoma drugs on the meshwork cell population. Res Clin Forums 1981;4:69-92.
15. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases.
J Cardiovasc Pharmacol 1993;22 Suppl 4:S1-S14.
16. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells.
Cardiovasc Res 1999;43:580-594.
17. Newby AC, George SJ. Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis.
Curr Opin Cardiol 1996;11:574-582.
18. Trachtman H, Futterweit S, Garg P, et al. Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells.
Biochem Biophys Res Commun 1996;218:704-708.
19. Murohara T, Witzenbichler B, Spyridopoulos I, et al. Role of endothelial nitric oxide synthase in endothelial cell migration.
Arterioscler Thromb Vasc Biol 1999;19:1156-1161.
20. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P.
J Clin Invest 1994;94:2036-2044.
21. Polansky JR, Weinreb RN, Baxter JD, Alvarado J. Human trabecular cells .I. Establishment in tissue culture and growth characteristics.
Invest Ophthalmol Vis Sci 1979;18:1043-1049.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
J Immunol Methods 1983;65:55-63.
23. Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids.
Anal Biochem 1982;126:131-138.
24. Okayama N, Ichikawa H, Coe L, et al. Exogenous NO enhances hydrogen peroxide-mediated neutrophil adherence to cultured endothelial cells.
Am J Physiol 1998;274(5 Pt 1):L820-L826.
25. Okouchi M, Okayama N, Shimizu M, et al. High insulin exacerbates neutrophil-endothelial cell adhesion through endothelial surface expression of intercellular adhesion molecule-1 via activation of protein kinase C and mitogen-activated protein kinase.
Diabetologia 2002;45:556-559.
26. Hogg P, Calthorpe M, Batterbury M, Grierson I. Aqueous humor stimulates the migration of human trabecular meshwork cells in vitro.
Invest Ophthalmol Vis Sci 2000;41:1091-1098.
27. Sato H, Kinoshita T, Takino T, et al. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2.
FEBS Lett 1996;393:101-104.
28. Oh DJ, Martin JL, Williams AJ, et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost.
Invest Ophthalmol Vis Sci 2006;47:953-963.
29. Maulik N, Engelman DT, Watanabe M, et al. Nitric oxide/carbon monoxide: a molecular switch for myocardial preservation during ischemia.
Circulation 1996;94(9 Suppl):II398-II406.
30. Eberhardt W, Beeg T, Beck KF, et al. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells.
Kidney Int 2000;57:59-69.
31. Zhang HJ, Zhao W, Venkataraman S, et al. Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species.
J Biol Chem 2002;277:20919-20926.
32. Upchurch GR Jr, Ford JW, Weiss SJ, et al. Nitric oxide inhibition increases matrix metalloproteinase-9 expression by rat aortic smooth muscle cells in vitro.
J Vasc Surg 2001;34:76-83.
33. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates.
Cardiovasc Res 2006;69:614-624.
34. Chen HH, Wang DL. Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells.
Mol Pharmacol 2004;65:1130-1140.
35. Sarkar R, Meinberg EG, Stanley JC, et al. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells.
Circ Res 1996;78:225-230.
36. Kawasaki K, Smith RS Jr, Hsieh CM, et al. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis.
Mol Cell Biol 2003;23:5726-5737.
37. Lau YT, Ma WC. Nitric oxide inhibits migration of cultured endothelial cells.
Biochem Biophys Res Commun 1996;221:670-674.
38. Kook H, Ahn KY, Lee SE, et al. Nitric oxide-dependent cytoskeletal changes and inhibition of endothelial cell migration contribute to the suppression of angiogenesis by RAD50 gene transfer.
FEBS Lett 2003;553:56-62.
39. Matsuo T. Basal nitric oxide production is enhanced by hydraulic pressure in cultured human trabecular cells.
Br J Ophthalmol 2000;84:631-635.
40. Haefliger IO, Dettmann E, Liu R. Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma.
Surv Ophthalmol 1999;58:99-105.
41. Schuman JS, Erickson K, Nathanson JA. Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys.
Exp Eye Res 1994;58:99-105.
42. Pfeilschifter J, Eberhardt W, Huwiler A. Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets.
Eur J Pharmacol 2001;429:279-286.
43. Kim JW, Heo H, Lee HW. Effect of nitric oxide on the proliferation of cultured porcine trabecular meshwork cells.
Korean J Ophthalmol 2003;17:1-6.
44. Noiri E, Peresleni T, Srivastava N, et al. Nitric oxide is necessary for a switch from stationary to locomoting phenotype in epithelial cells.
Am J Physiol 1996;270(3 Pt 1):C794-C802.
45. Beauvais F, Michel L, Dubertret L. Exogenous nitric oxide elicits chemotaxis of neutrophils in vitro.
J Cell Physiol 1995;165:610-614.
46. Noiri E, Lee E, Testa J, et al. Podokinesis in endothelial cell migration: role of nitric oxide.
Am J Physiol 1998;274(1 Pt 1):C236-C244.
47. Noiri E, Hu Y, Bahou WF, et al. Permissive role of nitric oxide in endothelin-induced migration of endothelial cells.
J Biol Chem 1997;272:1747-1752.
48. Genis L, Gonzalo P, Tutor AS, et al. Functional interplay between endothelial nitric oxide synthase and membrane type 1 matrix metalloproteinase in migrating endothelial cells.
Blood 2007;110:2916-2923.
49. Samples JR, Alexander JP, Acott TS. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone.
Invest Ophthalmol Vis Sci 1993;34:3386-3395.
50. Pang IH, Hellberg PE, Fleenor DL, et al. Expression of matrix metalloproteinases and their inhibitors in human trabecular meshwork cells.
Invest Ophthalmol Vis Sci 2003;44:3485-3493.
51. Ailenberg M, Silverman M. Cellular activation of mesangial gelatinase A by cytochalasin D is accompanied by enhanced mRNA expression of both gelatinase A and its membrane-associated gelatinase A activator (MT-MMP).
Biochem J 1996;313(Pt 3):879-884.
52. Ronkko S, Rekonen P, Kaarniranta K, et al. Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma.
Graefes Arch Clin Exp Ophthalmol 2007;245:697-704.
53. Keller KE, Aga M, Bradley JM, et al. Extracellular matrix turnover and outflow resistance.
Exp Eye Res 2009;88:676-682.
54. Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, et al. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma.
Invest Ophthalmol Vis Sci 2003;44:1117-1125.